Related Experiment Videos

Fixed combination of amlodipine/atorvastatin: from mechanisms to trials

Branislava Ivanovic1, Marijana Tadic

  • 11Clinical Centre of Serbia, Clinic for Cardiology, Belgrade, Serbia.

Journal of Cardiovascular Pharmacology and Therapeutics
|July 9, 2013
PubMed

Insights

Hypertension and dyslipidemia (DL) are common cardiovascular disease risk factors often inadequately treated due to poor adherence. Fixed-dose amlodipine/atorvastatin combination therapy offers a potential solution to improve treatment efficacy and patient adherence.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular diseases (CVDs) are a leading global cause of mortality.
  • Hypertension and dyslipidemia (DL) are prevalent and often co-occurring risk factors for CVDs.
  • Current treatments for hypertension and DL demonstrate insufficient efficacy, with many patients failing to achieve target blood pressure and low-density lipoprotein (LDL) levels.

Purpose of the Study:

  • To address the therapeutic challenges in managing co-existing hypertension and dyslipidemia.
  • To explore the potential of fixed-dose combination therapy in improving treatment outcomes.
  • To evaluate the benefits of amlodipine/atorvastatin fixed combination in patients with hypertension and DL.

Main Methods:

  • Review of existing studies on hypertension and dyslipidemia management.
  • Analysis of therapeutic failure reasons, including reduced patient adherence.
  • Assessment of fixed-dose combination therapy as a strategy to enhance adherence and efficacy.

Main Results:

  • Multidrug therapy for hypertension and DL often leads to reduced patient adherence.
  • Fixed-dose amlodipine/atorvastatin combination offers a single-pill treatment option.
  • This combination demonstrates a synergistic effect, a favorable safety profile, and good tolerability.

Conclusions:

  • Fixed-dose amlodipine/atorvastatin combination therapy presents a promising approach to overcome treatment challenges in patients with co-existing hypertension and dyslipidemia.
  • Improved adherence and synergistic effects contribute to better management of cardiovascular risk factors.
  • This strategy holds potential for enhancing overall cardiovascular disease prevention and management.

Keywords:
amlodipine/atorvastatincardiovascular diseasedyslipidemiafixed combinationhypertension

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...